Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influenza vaccination strategies after autologous hematopoietic stem cell transplantation
ACTRN12619000617167Phase 3Completed
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of influenza vaccine (quadrivalent, high-dose) and Vaxigrip in influenza (2 arms), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Seropositivity rate and Seroconversion rate. Started May 2019; status: completed.
02
Drugs
influenza vaccine (quadrivalent, high-dose)Vaxigrip
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12619000617167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000617167.